Xenetic Biosciences, Inc. 2013 Form 10-K Summary
Business Context and Reporting Period
This Annual Report covers the fiscal year ended December 31, 2013. Xenetic Biosciences, Inc. (formerly General Sales and Leasing, Inc.) is a clinical-stage biopharmaceutical company focused on developing drug therapies for orphan indications using three proprietary platforms: PolyXen (biopolymer conjugation), OncoHist (oncology therapy), and ImuXen (vaccine encapsulation). The company operates primarily through its subsidiary, Xenetic UK, following a reverse merger completed in January 2014. The company is headquartered in Lexington, Massachusetts, and trades on the OTCBB under the symbol "XBIO."
Key Financial Metrics
| Metric | 2013 | 2012 |
|---|---|---|
| Revenue | $1,000,000 | $293,603 |
| Net Loss | $(8,579,246) | $(6,328,340) |
| Research & Development Expenses | $3,060,306 | $1,943,504 |
| General & Administrative Expenses | $6,553,163 | $3,561,898 |
| Cash and Cash Equivalents (Year End) | $4,839,486 | $11,136,870 |
| Working Capital | $1,739,797 | $10,145,299 |
| Accumulated Deficit | $(58,306,999) | $(49,727,753) |
Note: Revenue in 2013 consisted entirely of a $1 million non-refundable upfront license fee from Baxter. There were no product sales.
Material Changes vs. Prior Period
- Revenue Increase: Revenue increased 241% to $1 million, driven by a single upfront payment from Baxter. In 2012, revenue was derived from supply services.
- Expense Growth: Operating expenses increased significantly. General and Administrative (G&A) expenses rose 84% to $6.55 million, primarily due to $2.6 million in legal, professional, and accounting costs associated with the reverse merger and relocation to the US. R&D expenses increased 58% to $3.06 million due to the commencement of clinical trials in Australia.
- Impairment: The company recorded no impairment charges in 2013, compared to a $1.09 million impairment of In-Process Research and Development (IPR&D) in 2012.
- Liquidity: Cash balances decreased by approximately $6.3 million due to operating losses and cash used in investing activities, despite the revenue inflow.
Guidance, Outlook, and Risks
Capital Requirements and Going Concern: Management states that as of December 31, 2013, the company had insufficient cash flow to fund operations beyond the first quarter of 2015. This raises substantial doubt about the company's ability to continue as a going concern without additional financing. The company estimates that the $10 million equity investment received from Baxter in January 2014 extends its runway to at least 12 months from the balance sheet date.
Strategic Outlook: The company plans to advance its drug candidates through in-house research and collaborations. Key milestones include:
- ErepoXen: Phase II trials in Australia and India; seeking out-licensing arrangements by end of 2014.
- OncoHist: Pre-clinical toxicity studies expected in H1 2014; US clinical trials planned for H1 2015.
Risks: The primary risk is the inability to raise additional working capital. Other risks include the failure of clinical trials, regulatory delays, reliance on third-party manufacturers (Serum Institute, SynBio), and the complexity of collaboration agreements.
Investor Verification Checklist
- Capital Runway: Verify the status of the $10 million Baxter investment and confirm current cash burn rates to assess the timeline for the next capital raise.
- Reverse Merger Accounting: Review the final purchase price allocation for the January 2014 acquisition of Xenetic UK, as preliminary valuations may change.
- Clinical Trial Progress: Monitor the status of the ErepoXen Phase II trials in Australia and India, and the OncoHist pre-clinical studies, as these are critical for future revenue milestones.
- Collaboration Milestones: Track Baxter's progress on the Factor VIII program, as future milestone payments (up to $100 million potential) are contingent on their performance.
- Stock Liquidity: Note that the stock trades on the OTCBB/OTCQB, which may limit liquidity and trading volume compared to major exchanges.